Encyclopedia   /  Cardiovascular Agents  /  Pharmaceutical Intermediates  /  Pharmaceutical
Amlodipine structure

Amlodipine

Amlodipine, 2-[, for the treatment of hypertension. Amlodipineis also marketed as a combination therapy with atorvastatinunder the tradename Norvasc for the management of highcholesterol and high blood pressure. View more+
 
1. Names and Identifiers
1.1 Name
Amlodipine
1.2 Synonyms
(R)-3-ethyl 5-methyl 2; (R,S)-2-[(2-aminoethoxy)methyl]-4-(2-chlorophenyl)-3-ethoxycarbonyl-5-methoxycarbonyl-6-methyl-1,4-dihydropyridine; 2-[(2-Aminoethoxy)methyl]-4-(2-chlorophenyl)-1,4-dihydro-6-methyl-3,5-pyridinedicarboxylic acid 3-ethyl 5-methyl Ester; 2-[(2-aminoethoxy)methyl]-4-(2-chlorophenyl)-3-ethoxycarbonyl-5-methoxycarbonyl-6-methyl-1,4-dihydropyridine; 3,5-Pyridinedicarboxylic acid, 2-((2-aminoethoxy)methyl)-4-(2-chlorophenyl)-1,4-dihydro-6-methyl-, 3-ethyl 5-methyl ester; 3,5-Pyridinedicarboxylic acid, 2-[(2-aminoethoxy)methyl]-4-(2-chlorophenyl)-1,4-dihydro-6-methyl-, 3-ethyl 5-methyl ester; 3,5-Pyridinedicarboxylic acid, 2-[(2-aminoethoxy)methyl]-4-(2-chlorophenyl)-1,4-dihydro-6-methyl-, 5-ethyl 3-methyl ester; 3,5-pyridinedicarboxylicacid,1,4-dihydro-2-((2-aminoethoxy)methyl)-4-(2-chlor; 3-ethyl 5-methyl ()-2-[(2-aminoethoxy)methyl]-4-(2-chlorophenyl)-1,4-dihydro-6-methyl-3,5-pyridine dicarboxylate; 3-Ethyl 5-methyl 2-[(2-aminoethoxy)methyl]-4-(2-chlorophenyl)-6-methyl-1,4-dihydro-3,5-pyridinedicarboxylate; 3-ethyl 5-methyl 2-[(2-aminoethoxy)methyl]-4-(2-chlorophenyl)-6-methyl-1,4-dihydropyridine-3,5-dicarboxylate; 3-Ethyl 5-methyl 2-{[(2-aminoethyl)oxy]methyl}-4-(2-chlorophenyl)-6-methyl-1,4-dihydropyridine-3,5-dicarboxylate; 3-ethyl-5-methyl-(4RS)-2-[(2-aminoethoxy)-methyl]-4-(2-chlorophenyl)-6-methyl-1,4-dihydropyridine-3,5-carboxylate benzene sulphonate; 3-ethyl5-methylester; 5-Ethyl 3-methyl 2-[(2-aminoethoxy)methyl]-4-(2-chlorophenyl)-6-methyl-1,4-dihydro-3,5-pyridinedicarboxylate; Amlocard; AMLODIPINE BASE; Amlodipine base (crystalline); Amlodipino; Amlodipinum; Amlodipinum [Latin]; Amlodis; Coroval; Istin; Lipinox; LOTREL; methyl ethyl 2-(2-aminoethoxymethyl)-4-(2-chlorophenyl)-6-methyl-1,4-dihydropyridine-3,5-dicarboxylate; MFCD00864687; Norvasc; T6M DHJ B1O2Z CVO2 DR BG& EVO1 F1; UNII:1J444QC288;
1.3 CAS No.
88150-42-9
1.4 CID
2162
1.5 EINECS
618-119-7
1.6 Molecular Formula
C20H25ClN2O5
1.7 Inchi
InChI=1S/C20H25ClN2O5/c1-4-28-20(25)18-15(11-27-10-9-22)23-12(2)16(19(24)26-3)17(18)13-7-5-6-8-14(13)21/h5-8,17,23H,4,9-11,22H2,1-3H3
1.8 InChkey
HTIQEAQVCYTUBX-UHFFFAOYSA-N
1.9 Canonical Smiles
CCOC(=O)C1=C(NC(=C(C1C2=CC=CC=C2Cl)C(=O)OC)C)COCCN
1.10 Isomers Smiles
CCOC(=O)C1=C(NC(=C(C1C2=CC=CC=C2Cl)C(=O)OC)C)COCCN
2. Properties
2.1 Solubility
75.3 mg/L
2.2 Appearance
Yellow Solid
2.3 Storage
-20°C Freezer
2.4 Chemical Properties
Yellow Solid
2.5 Color/Form
Yellow powder
2.6 Decomposition
Hazardous decomposition products formed under fire conditions - Carbon oxides, nitrogen oxides (NOx), sulfur oxides, hydrogen chloride gas. /Amlodipine besylate/
2.7 pKa
pKa 8.6 (Uncertain)
2.8 Water Solubility
H2O: 75.3 mg/L
2.9 Stability
Stable under recommended storage conditions. /Amlodipine besylate/
2.10 StorageTemp
Keep in dark place,Inert atmosphere,Store in freezer, under -20°C
3. Use and Manufacturing
3.1 Definition
ChEBI: A fully substituted dialkyl 1,4-dihydropyridine-3,5-dicarboxylate derivative, which is used for the treatment of hypertension, chronic stable angina and confirmed or suspected vasospastic angina.
3.2 Description

Amlodipine is a long-acting calcium channel blocker.Target: Calcium ChannelAmlodipine is a dihydropyridine calcium antagonist (calcium ion antagonist or slow-channel blocker) that inhibits the movement of calcium ions into vascular smooth muscle cells and cardiac muscle cells. Experimental data suggest amlodipine binds to both dihydropyridine and nondihydropyridine binding sites. The contractile processes of cardiac muscle and vascular smooth muscle are dependent upon the movement of ext

3.3 General Description
Amlodipine, 2-[, for the treatment of hypertension. Amlodipineis also marketed as a combination therapy with atorvastatinunder the tradename Norvasc for the management of highcholesterol and high blood pressure.
3.4 Methods of Manufacturing
(R, S)-Amlodipine besylate (5.342 g) was suspended in water (100 mL). The resultant mixture was brought to reflux while stirring. NaOH (0.4 g) was added to the resultant yellow solution, and the solution was allowed to reflux for a further 30 minutes. The mixture was subsequently allowed to cool overnight, and the resultant precipitate was filtered and dried under vacuum to provice 3.41 g (88.6 percent yield) of amlodipine (free base). Melting point 133-138Stage -3: Preparation of Amlodipine from Phthalimido amlodipine:Pure Phthalimido amlodipine (50 g) prepared as above is suspended in ethanolic methylamine (600 ml) and maintained for 17 hrs at 28°C - 32°C. The reaction mass is slowly poured into hot water (1200 ml) held at 50°C - 55°C over 45 min and mixed for about 1 hr at 50°C - 55°C. Reaction mass is slowly cooled and maintained for about 1 hr at 20°C - 25°C. The precipitated solid is filtered, washed the wet cake with water. Dried the product at 55°C - 60°C till constant weight.Dry weight of the Amlodipine base is 33.0 g (Yield: 87.2percent).Preparation of 3-Ethyl, 5-methyl (4RS) 2-[(2-AMINOETHOXY) METHYLL-4-(2-CHLOROPHENYL)-6-METHYL-1, 4-dihydro pyridine-3, 5-dicarboxylate (IV) A 100 L reactor was charged with 7.0 kg of phthaloyl amlodipine and 33.5 kg of toluene. Hydrazine hydrate 5. 1 kg was mixed with 10.0 kg of methanol in a 25 L reactor and was added into the stirring suspension of phthaloyl amlodipine at 22-24 °C. The solution was stirred for 7h at this temperature. The solid material phthalhydrazide was filtered off. The organic phase was washed with 2 X 20 L of MGSOI7 H20. After separating the phases, organic phase dried over 1.28 kg of MGS04 and filtered. The solution was concentrated to 1/3 of its original volume and 24 kg of n-hexanes was added. The mixture was cooled down to 0- 5 °C and kept at this temperature for 2h with stirring and then 12h without stirring. The product was filtered off and dried in oven under vacuum at 55 °C for 12h to give 4.6 kg of amlodipine base in 86.5percent yield as AWHITE POWDER. LH-NMR (CDC13) 6 7.85 (s, 1H), 7.20 (m, 4H), 5. 38 (s, 1H), 4.78 (d, 1H), 4.70 (d, 1H), 3.95 (m, 2H), 3.60 (s, 3H), 3.57 (d, 2H), 2.95 (M, 2H), 2.34 (s, 3H), 1.17 (t, 3H). 13C-NMR (CDCL3) No. 168.3, 167.4, 157.1, 146.2, 146.1, 144.6, 132.5, 131.7, 129.4, 127.5, 127.0, 104.0, 101.5, 73.5, 68.2, 60.0, 51.0, 41.3, 37.3, 19. 4, 14.5.General procedure: To a 50-ml glass round-bottom flask was added sequentially the primary amine 2 (1.0 mmol; aliphatic, aromatic or heteroaromatic; as free naked amine or as HCl, MsOH, TsOH or tartrate salt), FSO2N3 solution (containing 1.0 mmol FSO2N3, approximately 200 mM in DMF/MTBE 1:1, v/v, approximately 5 ml, volume adjusted according to the concentration; prepared according to the above procedure and diluted with equal volume of DMF) and aqueous KHCO3 solution (3.0 M, 1.33 ml, containing 4.0 mmol KHCO3). The reaction mixture was stirred for 5 min at room temperature, while monitoring by LC-MS. After completion, EtOAc (40 ml) was added and the mixture was washed sequentially with brine (60 ml × 6), water (60 ml × 2) and brine (60 ml), dried over Na2SO4, concentrated by rotary evaporation and dried under vacuum to afford the azide product 3. For products containing acidic functional groups, this extraction process was modified with acidified aqueous phase (acidified with aqueous HCl). Detailed procedures and the various modifications, as well as the characterization data for each compound, can be found in Supplementary Information 1.Accurately referred to as compound S23 take 500mg of 2.34mmol ie, dissolved in acetonitrile and added 1.0g About 2.53mmol amlodipine, i.e., 3-ethyl-5-methyl-2 - ((2-amino) methyl) -4- (2- Chloro) -6-methyl-1, 4-dihydropyridine-3, 5-dicarboxylic acid ester, 1.04g of potassium carbonate powder and about 7.59mmol 35a catalytic amount of about 0.23mmol mg NaI, the reaction system was transferred to 80 C in an oil bath at reflux, TLC Tracking and monitoring, 16h After completion of the reaction, the reaction was stopped, the organic solvent is evaporated, the reaction mixture was subjected to silica Gel column chromatography chromatography using the elution system containing 1% triethylamine, eluent petroleum ether and wherein Ethyl acetate in a volume ratio of 2:1-1:1 elution gradient, to give the compound of the present invention provides 7, 750mg, 54.1% yield.
3.5 Usage
A dihydropyridine calcium channel blocker; activity resides mainly in the (-)-isomer.
4. Safety and Handling
4.1 Safety Profile
Human systemic effects. Whenheated to decomposition it emits toxic vapors of NOx andCl-. Amlodipine Preparation Products And Raw materials Raw materials
4.2 Specification

The Amlodipine with the cas number 88150-42-9, is also called (1)3-Ethyl-5-methyl ( -)-2-((2-aminoethoxy)methyl)-4-(2-chlorphenyl)-1,4-dihydro-6-methyl-3,5-pyridindicarboxylat ; (2)3-Ethyl-5-methyl ( -)-2-((2-aminoethoxymethyl)-4-(o-chlorophenyl)-1,4-dihydro-6-methyl-3,5-pyridinedicarboxylate ; (3) Amlocard ; (4) Amlodipine ; (5) Amlodipino ; (6) Amlodipinum ; (7) Amlodis ; (8) Amlor ; (9) Coroval ; (10) Lipinox ; (11) Norvasc. It belongs to the following product categories: (1)Active Pharmaceutical Ingredients; (2)Dihydropyridine Class Chemicals; (3)Intermediates & Fine Chemicals; (4)Pharmaceuticals; (5)Calcium channel

Properties of Amlodipine are: (1)ACD/LogP: 4.16 ; (2)# of Rule of 5 Violations: 0 ; (3)ACD/LogD (pH 5.5): 1.23 ; (4)ACD/LogD (pH 7.4): 2.64 ; (5)ACD/BCF (pH 5.5): 1 ; (6)ACD/BCF (pH 7.4): 26.11 ; (7)ACD/KOC (pH 5.5): 5.14 ; (8)ACD/KOC (pH 7.4): 133.65 ; (9)#H bond acceptors: 7 ; (10)#H bond donors: 3 ; (11)#Freely Rotating Bonds: 11 ; (12)Polar Surface Area: 68.31??2 ; (13)Index of Refraction: 1.545 ; (14)Molar Refractivity: 105.41 cm3 ; (15)Molar Volume: 333 cm3 ; (16)Polarizability: 41.79 ×10-24cm3 ; (17)Surface Tension: 44.4 dyne/cm ; (18)Density: 1.227 g/cm3 ; (19)Flash Point: 272.6 °C ; (20)Enthalpy of Vaporization: 80.17 kJ/mol ; (21)Boiling Point: 527.2 °C at 760 mmHg ; (22)Vapour Pressure: 3.34E-11 mmHg at 25°C

The Amlodipine appears to be Yellow Solid. It is used as an anti-hypertensive and in the treatment of angina because it is a long-acting calcium channel blocker. Seemimg Like other calcium channel blockers, Amlodipine reduce blood pressure by relaxing the smooth muscle in the arterial wall, decreasing peripheral resistance. Besides, it increases blood flow to the heart muscle in angina. Adverse effcts include common headache, fatigue, insomnia, edema, abdominal pain, nausea, dizziness, palpitation and red face. Rare rash, itching, expiratory dyspnea, muscle spasm and indigestion. Rarely have myocardial infarction and chest. It can have edema, headache, dizziness, weakness, etc.

The Amlodipine can react with nicotinic acid to obtain 4-(2-chloro-phenyl)-2-methyl-6-{2-[(pyridine-3-carbonyl)-amino]-ethoxymethyl}-1,4-dihydro-pyridine-3,5-dicarboxylic acid 5-ethyl ester 3-methyl ester.
Reaction condition is CH2Cl2 as solvent under ambient temperature for 16 hour(s). Yield is 57 %.
?????????????????
?

You can still convert the following datas into molecular structure :
1. SMILES: Clc1ccccc1C2C(=C(/N/C(=C2/C(=O)OCC)COCCN)C)\C(=O)OCCopyCopied
2. InChI:?InChI=1/C20H25ClN2O5/c1-4-28-20(25)18-15(11-27-10-9-22)23-12(2)16(19(24)26-3)17(18)13-7-5-6-8-14(13)21/h5-8,17,23H,4,9-11,22H2,1-3H3

The Amlodipine toxic data can be showed in the following sheet.
?

Organism Test Type Route Reported Dose (Normalized Dose) Effect Source
child TDLo oral 400ug/kg (0.4mg/kg) VASCULAR: BP LOWERING NOT CHARACTERIZED IN AUTONOMIC SECTION American Journal of Emergency Medicine. Vol. 18, Pg. 581, 2000.
women LDLo oral 1400ug/kg (1.4mg/kg) CARDIAC: PULSE RATE INCREASE WITHOUT FALL IN BP

VASCULAR: BP LOWERING NOT CHARACTERIZED IN AUTONOMIC SECTION
Journal of Toxicology, Clinical Toxicology. Vol. 33, Pg. 253, 1995.
women TDLo oral 600ug/kg/3D-I (0.6mg/kg) SENSE ORGANS AND SPECIAL SENSES: OTHER CHANGES: OLFACTION

BLOOD: HEMORRHAGE

BLOOD: THROMBOCYTOPENIA
Annals of Pharmacotherpy. Vol. 33, Pg. 1126, 1999.

4.3 Toxicity
TDLo orl-chd: 400 mg/kg:BPR AJEMEN 18,581,2000
5. MSDS

2.Hazard identification

2.1 Classification of the substance or mixture

Acute toxicity - Oral, Category 3

Serious eye damage, Category 1

Specific target organ toxicity \u2013 repeated exposure, Category 2

Hazardous to the aquatic environment, short-term (Acute) - Category Acute 1

Hazardous to the aquatic environment, long-term (Chronic) - Category Chronic 1

2.2 GHS label elements, including precautionary statements

Pictogram(s)
Signal word

Danger

Hazard statement(s)

H301 Toxic if swallowed

H318 Causes serious eye damage

H373 May cause damage to organs through prolonged or repeated exposure

H400 Very toxic to aquatic life

H410 Very toxic to aquatic life with long lasting effects

Precautionary statement(s)
Prevention

P264 Wash ... thoroughly after handling.

P270 Do not eat, drink or smoke when using this product.

P280 Wear protective gloves/protective clothing/eye protection/face protection.

P260 Do not breathe dust/fume/gas/mist/vapours/spray.

P273 Avoid release to the environment.

Response

P301+P310 IF SWALLOWED: Immediately call a POISON CENTER/doctor/\u2026

P321 Specific treatment (see ... on this label).

P330 Rinse mouth.

P305+P351+P338 IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.

P310 Immediately call a POISON CENTER/doctor/\u2026

P314 Get medical advice/attention if you feel unwell.

P391 Collect spillage.

Storage

P405 Store locked up.

Disposal

P501 Dispose of contents/container to ...

2.3 Other hazards which do not result in classification

none

6. Synthesis Route
88150-42-9Total: 7 Synthesis Route
 
638-07-3
638-07-3 228 Suppliers
 
88150-42-9
88150-42-9 316 Suppliers
 
88150-62-3
88150-62-3 106 Suppliers
 
88150-42-9
88150-42-9 316 Suppliers
7. Precursor and Product
precursor:
product:
8. Computed Properties
9.Other Information
Usage
A calcium channel antagonist with potent antioxidant activityAmlodipine is an L-type calcium channel protein inhibitor and blocker. It is used in combination with the angiotensin receptor blocker olmesartan. Further, it acts as a dihydropyridine calcium channel blocker. It is used as an anti-hypertensive. It is involved in the treatment of angina and to lower blood pressure. In addition to this, it is used to prevent chest pain and in coronary artery disease.
Description
Amlodipine is a dihydropyridine L-type calcium channel blocker that selectively inhibits calcium influx in cardiac and vascular smooth muscle. Acting as a vasodilator, amlodipine reduces blood pressure by relaxing the smooth muscle in the arterial wall, decreasing total peripheral resistance. It inhibits calcium-induced contractions in depolarized rat aorta with an IC50 value of 1.9 nM, displaying a slow rate of association and dissociation in isolated vascular and cardiac tissues. Amlodipine also demonstrates actions independent of L-type calcium channel blockade by regulating membrane fluidity and cholesterol deposition, stimulating nitric oxide production, acting as an antioxidant, and regulating matrix deposition in vitro and in vivo. Formulations containing amlodipine have been used in the treatment of hypertension.
Chemical Properties
Yellow Solid
Uses
A dihydropyridine calcium channel blocker; activity resides mainly in the (-)-isomer.
Uses
anti-hypertensive;calcium channel blocker
Uses
A deuterated dihydropyridine calcium channel blocker.;Application of Labeled APIs: Labeled Amlodipine, intended for use as an internal standard for the quantification of Amlodipine by GC- or LC-mass spectrometry.
Definition
ChEBI: A fully substituted dialkyl 1,4-dihydropyridine-3,5-dicarboxylate derivative, which is used for the treatment of hypertension, chronic stable angina and confirmed or suspected vasospastic angina.
Brand name
Norvasc (Pfizer).
General Description
Amlodipine, 2-[, for the treatment of hypertension. Amlodipineis also marketed as a combination therapy with atorvastatinunder the tradename Norvasc for the management of highcholesterol and high blood pressure.
Hazard
Human systemic effects.
Safety Profile
Human systemic effects. Whenheated to decomposition it emits toxic vapors of NOx andCl-.
Storage Conditions
(R, S)-Amlodipine besylate (5.342 g) was suspended in water (100 mL). The resultant mixture was brought to reflux while stirring. NaOH (0.4 g) was added to the resultant yellow solution, and the solution was allowed to reflux for a further 30 minutes. The mixture was subsequently allowed to cool overnight, and the resultant precipitate was filtered and dried under vacuum to provice 3.41 g (88.6 percent yield) of amlodipine (free base). Melting point 133-138Stage -3: Preparation of Amlodipine from Phthalimido amlodipine:Pure Phthalimido amlodipine (50 g) prepared as above is suspended in ethanolic methylamine (600 ml) and maintained for 17 hrs at 28°C - 32°C. The reaction mass is slowly poured into hot water (1200 ml) held at 50°C - 55°C over 45 min and mixed for about 1 hr at 50°C - 55°C. Reaction mass is slowly cooled and maintained for about 1 hr at 20°C - 25°C. The precipitated solid is filtered, washed the wet cake with water. Dried the product at 55°C - 60°C till constant weight.Dry weight of the Amlodipine base is 33.0 g (Yield: 87.2percent).Preparation of 3-Ethyl, 5-methyl (4RS) 2-[(2-AMINOETHOXY) METHYLL-4-(2-CHLOROPHENYL)-6-METHYL-1, 4-dihydro pyridine-3, 5-dicarboxylate (IV) A 100 L reactor was charged with 7.0 kg of phthaloyl amlodipine and 33.5 kg of toluene. Hydrazine hydrate 5. 1 kg was mixed with 10.0 kg of methanol in a 25 L reactor and was added into the stirring suspension of phthaloyl amlodipine at 22-24 °C. The solution was stirred for 7h at this temperature. The solid material phthalhydrazide was filtered off. The organic phase was washed with 2 X 20 L of MGSOI7 H20. After separating the phases, organic phase dried over 1.28 kg of MGS04 and filtered. The solution was concentrated to 1/3 of its original volume and 24 kg of n-hexanes was added. The mixture was cooled down to 0- 5 °C and kept at this temperature for 2h with stirring and then 12h without stirring. The product was filtered off and dried in oven under vacuum at 55 °C for 12h to give 4.6 kg of amlodipine base in 86.5percent yield as AWHITE POWDER. LH-NMR (CDC13) 6 7.85 (s, 1H), 7.20 (m, 4H), 5. 38 (s, 1H), 4.78 (d, 1H), 4.70 (d, 1H), 3.95 (m, 2H), 3.60 (s, 3H), 3.57 (d, 2H), 2.95 (M, 2H), 2.34 (s, 3H), 1.17 (t, 3H). 13C-NMR (CDCL3) No. 168.3, 167.4, 157.1, 146.2, 146.1, 144.6, 132.5, 131.7, 129.4, 127.5, 127.0, 104.0, 101.5, 73.5, 68.2, 60.0, 51.0, 41.3, 37.3, 19. 4, 14.5.General procedure: To a 50-ml glass round-bottom flask was added sequentially the primary amine 2 (1.0 mmol; aliphatic, aromatic or heteroaromatic; as free naked amine or as HCl, MsOH, TsOH or tartrate salt), FSO2N3 solution (containing 1.0 mmol FSO2N3, approximately 200 mM in DMF/MTBE 1:1, v/v, approximately 5 ml, volume adjusted according to the concentration; prepared according to the above procedure and diluted with equal volume of DMF) and aqueous KHCO3 solution (3.0 M, 1.33 ml, containing 4.0 mmol KHCO3). The reaction mixture was stirred for 5 min at room temperature, while monitoring by LC-MS. After completion, EtOAc (40 ml) was added and the mixture was washed sequentially with brine (60 ml × 6), water (60 ml × 2) and brine (60 ml), dried over Na2SO4, concentrated by rotary evaporation and dried under vacuum to afford the azide product 3. For products containing acidic functional groups, this extraction process was modified with acidified aqueous phase (acidified with aqueous HCl). Detailed procedures and the various modifications, as well as the characterization data for each compound, can be found in Supplementary Information 1.Accurately referred to as compound S23 take 500mg of 2.34mmol ie, dissolved in acetonitrile and added 1.0g About 2.53mmol amlodipine, i.e., 3-ethyl-5-methyl-2 - ((2-amino) methyl) -4- (2- Chloro) -6-methyl-1, 4-dihydropyridine-3, 5-dicarboxylic acid ester, 1.04g of potassium carbonate powder and about 7.59mmol 35a catalytic amount of about 0.23mmol mg NaI, the reaction system was transferred to 80 C in an oil bath at reflux, TLC Tracking and monitoring, 16h After completion of the reaction, the reaction was stopped, the organic solvent is evaporated, the reaction mixture was subjected to silica Gel column chromatography chromatography using the elution system containing 1% triethylamine, eluent petroleum ether and wherein Ethyl acetate in a volume ratio of 2:1-1:1 elution gradient, to give the compound of the present invention provides 7, 750mg, 54.1% yield.
10. Toltal 280 Suppliers View more
Tel: Update Time:2024/11/15
Tel: Update Time:2024/11/15
Tel: Update Time:2024/11/14
Tel: Update Time:2023/06/28
Tel: Update Time:2024/11/15
11. Related Questions
Have you ever wondered about the applications and effects of Amlodipine in pharmaceuticals?Amlodipine is a commonly used drug ingredient, belonging to the class of calcium channel blockers. It has various applications and effects in the pharmaceutical field, and in this article, we will exp..
Why is Amlodipine so popular? Amlodipine, a third-generation dihydropyridine calcium channel blocker, is a typical drug in the alkaline, long-acting dihydropyridine calcium channel blocker class. It acts on the dihydropyridine bi..
Who is Amlodipine suitable for? Amlodipine is a calcium channel blocker primarily used for the treatment of hypertension and coronary artery disease. It is important to pay attention to the dosage, contraindications, precautions, a..
What should be noted when taking Amlodipine? Amlodipine is highly effective in treating hypertension and angina during daily use. Understanding the precautions after taking this medication can help ensure safety and achieve better results in ma..
12. Realated Product Infomation
 
 
 
Cancel
 
Popular Searches
Request For Quotation